Alpha Teknova (TKNO) Q2 FY26 earnings call

Alpha Teknova delivered a record-breaking second quarter, achieving its highest-ever quarterly revenue with broad-based growth across most target markets. The company raised its full-year revenue guidance, reflecting confidence in its commercial investments and the underlying market recovery, despite continued softness in the cell and gene therapy segment. Strategic initiatives like the Build-Tek AI configurator are expected to enhance customer engagement and custom product adoption.